DexCom Stock Issuance Proceeds decreased by 8.6% to $12.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 10.6%, from $14.20M to $12.70M.
Higher proceeds often correlate with employee participation in stock-based compensation programs rather than external capital raising.
Cash inflows resulting from the issuance of common stock, typically through employee stock option exercises or equity co...
Standard for large-cap companies with significant equity-based compensation programs.
proceeds_from_stock_issuance| Q3 '21 | Q1 '22 | Q3 '22 | Q1 '23 | Q3 '23 | Q1 '24 | Q3 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.60M | $10.10M | $12.40M | $12.30M | $14.30M | $13.40M | $14.80M | $14.20M | $13.90M | $12.70M |
| QoQ Change | — | -12.9% | +22.8% | -0.8% | +16.3% | -6.3% | +10.4% | -4.1% | -2.1% | -8.6% |
| YoY Change | — | — | +6.9% | +21.8% | +15.3% | +8.9% | +3.5% | +6.0% | -6.1% | -10.6% |